ruxolitinib

signal transducer and activator of transcription 1 ; Mus musculus







8 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33509790 Antitumor T-cell Immunity Contributes to Pancreatic Cancer Immune Resistance. 2021 Apr 1
2 33811972 Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease. 2021 Jun 3
3 33901462 JAK/STAT pathway promotes the progression of diabetic kidney disease via autophagy in podocytes. 2021 Jul 5 1
4 34440089 Ruxolitinib Combined with Gemcitabine against Cholangiocarcinoma Growth via the JAK2/STAT1/3/ALDH1A3 Pathway. 2021 Jul 24 3
5 31968212 JAK-STAT-dependent regulation of scavenger receptors in LPS-activated murine macrophages. 2020 Mar 15 1
6 29295936 Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma. 2018 Jan 16 1
7 28405527 JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. 2017 1
8 27222478 Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. 2016 Jul 7 1